Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy
Have failed, refused, or have been deemed ineligible for standard therapy
Measurable disease
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70
You may not be if
Primary diagnosis of lymphoma or central nervous system (CNS) malignancy
History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years
Evidence of active cerebral/meningeal disease
Clareo Health | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
